Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1998-5-19
pubmed:abstractText
Administration of growth factors is emerging as a new therapeutic approach for the enhancement of collateral vessel formation in the ischemic heart. We have investigated the effects of intramyocardial delivery of FGF-2 in the presence and absence of heparin on angiogenesis in a porcine model of myocardial infarction. Yorkshire pigs were subjected to myocardial infarction by the placement of an embolization coil in the left anterior descending artery (n = 5). Four to five weeks after creation of an infarct, FGF-2 (10 micrograms) alone or in complex with heparin, heparan sulfate, or heparin agarose beads was injected either into the normal myocardium or along the infarct border area. Histologic evaluation of each injection site was performed 4 to 5 weeks post-injection. The effect of FGF-2 on angiogenesis was evaluated by determining the number of capillaries (diameter < 20 microns (and arterioles (> 20 microns with tunica media) in each area observed. The number of capillaries were not affected by the treatment of FGF-2 both in normal myocardium and infarct border area. However, in the normal myocardium, the number of arterioles were increased with the treatment of FGF-2 alone (85 +/- 59%, P < 0.04), FGF-2 plus heparin (281 +/- 193%, P < 0.004) and FGF-2-coated heparin beads (241 +/- 141%, P < 0.01), as compared to control. Delivery of FGF-2 into the infarct border area, also increased the number of arterioles when FGF-2 was given with heparin (736 +/- 154%, P < 0.001) or heparin beads (700 +/- 109%, P < 0.001), as compared to control. FGF-2 administered with heparin was the most effective method of enhancing angiogenesis as compared to FGF-2 alone, FGF-2 plus heparan sulfate, or FGF-2 coated heparin agarose beads.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0300-8428
pubmed:author
pubmed:issnType
Print
pubmed:volume
93
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
30-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:9538935-Affinity Labels, pubmed-meshheading:9538935-Animals, pubmed-meshheading:9538935-Capillaries, pubmed-meshheading:9538935-Collateral Circulation, pubmed-meshheading:9538935-Coronary Vessels, pubmed-meshheading:9538935-Dose-Response Relationship, Drug, pubmed-meshheading:9538935-Fibroblast Growth Factor 2, pubmed-meshheading:9538935-Follow-Up Studies, pubmed-meshheading:9538935-Heart, pubmed-meshheading:9538935-Hemodynamics, pubmed-meshheading:9538935-Heparitin Sulfate, pubmed-meshheading:9538935-Injections, Intramuscular, pubmed-meshheading:9538935-Male, pubmed-meshheading:9538935-Myocardial Infarction, pubmed-meshheading:9538935-Neovascularization, Pathologic, pubmed-meshheading:9538935-Recombinant Proteins, pubmed-meshheading:9538935-Sepharose, pubmed-meshheading:9538935-Swine
pubmed:year
1998
pubmed:articleTitle
Effect of basic fibroblast growth factor on angiogenesis in the infarcted porcine heart.
pubmed:affiliation
Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans 70112, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't